GSK to acquire CMG1A46 from Chimagen Biosciences to expand immunology pipeline
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
CMG1A46 is an investigational T cell-engager with potential to deeply deplete uncontrolled B cells present in autoimmune diseases such as lupus
Prometheus Biosciences’ comprehensive data set enables target discovery and precision medicine approach in inflammation and immunology
Dupixent peak sales ambition raised to more than €13 billion
The expansion will significantly enhance AbbVie’s ability to meet growing global demand for biologics, particularly in oncology and immunology
Pfizer will participate in TrumpRx.gov, a direct-to-patient purchasing platform offering discount up to 85%
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
Tezspire nearly eliminated the need for surgery, reducing surgical intervention by 98 per cent
Program provides access to Lilly-trained artificial intelligence to help accelerate breakthrough medicines
Subscribe To Our Newsletter & Stay Updated